Ophthalmic medication delivery applications using liposomal formulations have received much research during the last decade. This study set out to determine whether nano-vesicles modified with propylene glycol (PG) and tacrolimus (0.01%) applied topically may help alleviate symptoms of experimental dry eye syndrome (DES) in rabbits. PNVs treatment and tacrolimus solution 0.01% were compared to untreated and healthy patients. The clinical results for PNV-treated animals improved, with higher tear production and a decreased TBUT. Most metrics were within normal range, and the PNV therapy was shown to be more successful than the TAC solution. Therefore, tacrolimus PNV formulation (0.01%) may provide a promising therapeutic option for dry eye condition.

Tacrolimus Dry eye syndrome Ocular Proglycosomes Nanovesicles